RESMED INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ResMed (RMD) director Peter C. Farrell sold 970 shares at $234.73 each under a Rule 10b5-1 trading plan on September 2, 2026. He now holds 51,803 shares directly. The sale was part of a pre-arranged plan adopted in August 2025.
ResMed Inc. (ASX: RMD) shares are trading at $31.89. The company, a global leader in sleep apnoea treatment, sees significant growth potential as only a fraction of the estimated 1 billion global cases are diagnosed. ResMed expects US cases to reach 77 million by 2050. The company's valuation, with a PE ratio of under 19 times forecast FY27 earnings, is considered attractive by analysts.
Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.
Over the past 7 days, alphai's AI scored 5 news stories mentioning RMD (RESMED INC). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.
Recent RMD coverage spans financial news, earnings and regulation.
In the last 30 days, RMD insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.1M). The most active reporter was FARRELL PETER C with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Small insider sale of roughly $228K; unlikely to move price materially.
No immediate price impact; the piece is a qualitative assessment.
In‑line results with a modest price gain.
Mixed results with modest upside potential.
Resmed faces a product safety recall affecting specific ventilator models.
alphai scores every news story that mentions RMD with an AI model for sentiment and relevance, and aggregates insider trades from RESMED INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
ResMed (RMD) director Peter C. Farrell sold 970 shares at $234.73 each under a Rule 10b5-1 trading plan on September 2, 2026. He now holds 51,803 shares directly. The sale was part of a pre-arranged plan adopted in August 2025.
1 min readResMed Inc. (ASX: RMD) shares are trading at $31.89. The company, a global leader in sleep apnoea treatment, sees significant growth potential as only a fraction of the estimated 1 billion global cases are diagnosed. ResMed expects US cases to reach 77 million by 2050. The company's valuation, with a PE ratio of under 19 times forecast FY27 earnings, is considered attractive by analysts.
2 min readInsulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.
3 min readiRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.
2 min readThe FDA issued Class I recalls for certain convenience kits by Medline and Medical Action, and for Astral ventilators by ResMed, due to safety concerns. Baxter voluntarily recalled a specific lot of IV solution due to particulate contamination. The recalls may impact the companies' operations and financial performance.
1 min readThe FDA issued early alerts for heart pump controllers made by Boston Scientific, following reports of 3 deaths and dozens of injuries. The company acknowledged a cybersecurity issue on Aug. 25. The FDA also identified Class I recalls for products by ResMed, Medline, and Medical Action, citing safety concerns.
2 min readResMed (RMD) has nine 'Strong Buy' ratings. Analysts' average price target is $238.27, a 1.4% premium to current levels. Wells Fargo cut its target to $215, keeping an 'Equal Weight' rating.
1 min readResMed (RMD) announced Carol Burt as Lead Director, changed auditors to PwC, and launched a sleep apnea awareness campaign with NASCAR. The company projects $6.5B revenue and $1.8B earnings by 2029, with analysts estimating 5% upside. Investors focus on sleep apnea awareness and reimbursement risks.
2 min readResMed (RMD) announced governance changes, including a new Lead Director and auditor. The stock has seen a 18.56% increase over the past month but is down 5.43% year-to-date. Analysts suggest the stock is undervalued, with a fair value estimate of $247.93, citing strategic investments and market potential. Risks include competition and component constraints.
2 min readResMed (RMD) reported Q4 FY2026 results on Aug. 6. Quarterly revenue rose 9% to $1.5B and non-GAAP EPS increased 16% to $2.95. Full-year revenue grew 10% and free cash flow exceeded $1.6B. The company cited sleep growth drivers but said Astral sales were paused due to a field safety action, with a $42M provision.
7 min read
